Business Wire

Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor

Peer-reviewed study in Cell Reports Medicine demonstrates that N17350 delivers selective, immune-activating tumor killing across solid tumor types N17350 targets a cancer vulnerability, via the ELANE ...
Business Wire

Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at SITC 2024

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma, a private biotech company pioneering pan-cancer therapeutics that leverage the ELANE pathway, today announced the presentation of new preclinical data ...
Morningstar

Consegna Pharma Highlights Innovative Modeling and Simulation Strategy as FDA Concurs with Regulatory Pathway for CP217 to Prevent Fentanyl Epidemic Deaths

Prevention of Renarcotization after Rescue from Opioid Overdose is a New Indication and Planned Clinical Studies will be Supported by Pioneering a First-of-Its-Kind, Capital Efficient, Modeling and ...
Morningstar

Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor

Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the publication of foundational preclinical data in Cell ...